Becton, Dickinson and Company BDX
183.82
4.59
2.56%
as of 25 Sep
- Market cap
- $48.8B
- P/E
- 55.4×
Follow BDX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Becton, Dickinson and Company (BDX) Return on equity
Becton, Dickinson and Company's return on equity over the twelve months to 30 June 2026 was 3.77%, down 2.8 percentage points from fiscal 2025 (6.54%). Over the past ten years it has ranged from 0.94% (fiscal 2018) to 13.2% (fiscal 2016); the current reading is higher than 45% of that period. That is above the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 6.54% | (0.06) |
| FY2024 | 6.60% | 1.02 |
| FY2023 | 5.58% | (1.32) |
| FY2022 | 6.90% | (1.54) |
| FY2021 | 8.44% | 5.02 |
| FY2020 | 3.42% | (1.72) |
| FY2019 | 5.14% | 4.20 |
| FY2018 | 0.94% | (9.07) |
| FY2017 | 10.0% | (3.18) |
| FY2016 | 13.2% | 1.81 |
Against its own ten years
Low 0.94%
High 13.2%
Ten-year median
6.60%
Current reading's percentile
45
Return on equity against peers
| Company | Return on equity |
|---|---|
| SOLV Solventum Corporation compare | 34.0% |
| RMD ResMed Inc. compare | 24.3% |
| WST West Pharmaceutical Services, Inc. compare | 19.1% |
| ISRG Intuitive Surgical, Inc. compare | 17.3% |
| BDX Becton, Dickinson and Company | 3.77% |
| ALC Alcon compare | 2.94% |
| RGEN Repligen Corporation compare | 1.99% |
| MDLN Medline Inc. compare | 0.00% |
| BAX Baxter International Inc. compare | −15.8% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on BDX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement